Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2

Conditions

Myasthenia Gravis 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Hodgkin Disease 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × rhoA GTP-Binding Protein × Clear all
NCT05218096 2025-01-09

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 2 Terminated
70 enrolled 14 charts

Myasthenia Gravis

NCT02867618 2021-07-16

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Columbia University

Phase 1/2 Terminated
14 enrolled 9 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03178201 2021-07-16

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Columbia University

Phase 2 Terminated
5 enrolled 5 charts
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡